Two Novel Bioactive Peptides from Antarctic Krill with Dual Angiotensin Converting Enzyme and Dipeptidyl Peptidase IV Inhibitory Activities.
Ji. Wei W; Zhang. Chaohua C; Ji. Hongwu H
Key Findings
- Two krill-derived peptides (Lys‑Val‑Glu‑Pro‑Leu‑Pro and Pro‑Ala‑Leu) inhibit both ACE and DPP‑IV enzymes in vitro.
- The IC50 values are around 0.6‑0.9 mg/mL, indicating moderate potency against both targets.
- Not all fractions from the krill protein hydrolysate showed dual activity; only these specific sequences did.
Practical Outcomes
- For biohackers, the study points to new candidate compounds that could be synthesized and tested for blood‑pressure and blood‑sugar control. However, no human or animal data, dosing guidelines, or safety information are provided yet, so the immediate actionable step is limited to considering these sequences for further experimentation or supplement formulation after more research.
Summary
Scientists found two short protein pieces (peptides) from Antarctic krill that can block two enzymes linked to high blood pressure and high blood sugar. In lab tests, these peptides stopped the enzymes at fairly low concentrations, suggesting they might help manage hypertension and diabetes if they work the same way in the body.
Abstract
Inhibition of dipeptidyl peptidase IV (DPP-IV) and angiotensin converting enzyme (ACE) are considered useful in managing 2 often associated conditions: diabetes and hypertension. In this study, corolase PP was used to hydrolyze Antarctic krill protein. The hydrolysate (AKH) was isolated by ultrafiltration and purified by size-exclusion chromatography, ion exchange chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC) sequentially. The in vitro inhibitory activities of all AKHs and several fractions obtained against ACE and DPP-IV were assessed. Two peptides, purified with dual-strength inhibitory activity against ACE and DPP-IV, were identified by TOF-MS/MS. Results indicated that not all fractions exhibited dual inhibitory activities of ACE and DPP-IV. The purified peptide Lys-Val-Glu-Pro-Leu-Pro had half-maximal inhibitory concentrations (IC<sub>50</sub> ) of 0.93±0.05 and 0.73±0.04 mg/mL against ACE and DPP-IV, respectively. The other peptide Pro-Ala-Leu had IC<sub>50</sub> values of 0.64±0.05 and 0.88±0.03 mg/mL against ACE and DPP-IV, respectively. This study firstly reported the sequences of dual bioactive peptides from Antarctic krill proteins, further provided new insights into the bioactive peptides responsible for the ACE and DPP-IV inhibitory activities from the Antarctic krill protein hydrolysate to manage hypertension and diabetes.
Study Information
pubmed
2017
2017-05-27T00:00:00.000Z
10.1111/1750-3841.13735
42
38